{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-24-002009","form_type":"8-K","ticker":"ABT","cik":"0000001800","company_name":"ABBOTT LABORATORIES","filed_at":"2024-01-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:25.578878+00:00","generated_at":"2026-06-06T19:23:06.154909+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Abbott Q4 adj EPS $1.19, base organic +11%; FY24 guide $4.50-$4.70","bullets":["Q4 reported sales $10.241B (+1.5%); organic base business growth +11.0% excluding COVID tests.","GAAP diluted EPS $0.91; adjusted diluted EPS $1.19. Full-year 2023 adjusted EPS $4.44.","FY2024 guidance: GAAP EPS $3.20-$3.40, adjusted EPS $4.50-$4.70; organic sales growth 8-10% ex-COVID.","Medical Devices sales +17.5% reported; FreeStyle Libre revenue $1.4B (+23.8% organic).","Nutrition sales +12.2% reported, +13.9% organic; U.S. infant formula regained market-leading position."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-24-002009","json":"https://secwatch.observer/filing/0001628280-24-002009.json","markdown":"https://secwatch.observer/filing/0001628280-24-002009.md","text":"https://secwatch.observer/filing/0001628280-24-002009.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/abt-20240124.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T19:23:06.154909+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"a910e1866243ed06da3c733b5d25f8bfea3da58e","claim":"ABBOTT LABORATORIES reported full-year 2024 results: EPS full-year adjusted diluted EPS of $4.50 to $4.70. Guidance initiated.","evidence_excerpt":"Abbott issues full-year 2024 guidance for diluted EPS on a GAAP basis of $3.20 to $3.40 and full-year adjusted diluted EPS of $4.50 to $4.70.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"full-year 2024"},{"label":"EPS","value":"full-year adjusted diluted EPS of $4.50 to $4.70"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"guidance update"}],"fact_type":"earnings_release"},{"claim_id":"dabb1aec8de447efd3f4512174eb007014268660","claim":"ABBOTT LABORATORIES reported the fourth quarter ended Dec. 31, 2023 results: EPS Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19. Guidance initiated.","evidence_excerpt":"On January 24, 2024, Abbott Laboratories announced its results of operations for the fourth quarter and full year 2023.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1800/000162828024002009/0001628280-24-002009-index.htm","confidence":0.87,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter ended Dec. 31, 2023"},{"label":"EPS","value":"Fourth-quarter GAAP diluted EPS of $0.91 and adjusted diluted EPS of $1.19"},{"label":"Guidance","value":"initiated"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}